***Background.*** Vaccine preventable infection is associated with high morbidity and mortality in solid organ transplant (SOT) recipients. Vaccination is most effective if it is given pre-transplant, prior to the initiation of chronic immunosuppression. Despite these strong recommendations, there is limited data about pre-transplant vaccination status among listed transplant candidates. We examined vaccination status of patients in our renal transplant program to identify the gaps and to use this information for future protocol to improve the vaccination rates.

***Methods.*** We performed chart review of consecutive patients who were listed as a potential kidney transplant candidate (status 7 or inactive) at Hahnemann University Hospital to evaluate whether or not they had received appropriate vaccinations for pneumococcus, influenza, and tetanus. Hepatitis B was evaluated by the presence or absence of suitable titers of antibodies against hepatitis B virus.

***Results.*** One-hundred two patients were evaluated. Median age of cohort was 52 year-old, 66.7% were receiving dialysis at the time of evaluation. Immunization rates were low with 30.4% having received pneumococcal vaccine, 43% received influenza vaccine, and 9.8% received tetanus vaccine. Patients who received other vaccines i.e., influenza (63.6% vs 5.2%, p \< 0.01) and tetanus (25.8% vs 2.8%, p \< 0.01) were more likely to receive pneumococcal vaccine. Immunity against hepatitis B virus was found in 41.6% of listed patients and was more likely if the patients were receiving dialysis (70% vs 32.3%, p \< 0.01).

***Conclusion.*** In a sequential cohort of patients listed for kidney transplantation, we found that the overall immunization rate of commonly vaccine preventable infection was low. This suggests that, there remains a significant gap between recommendations and actual vaccination rates for this high risk population. To overcome these challenges, we suggest: (1) augmenting current education for both transplant professionals and listed patients, (2) develop quality matrix for appropriate vaccination, (3) simplify vaccination delivery (4) work on resolving financial barriers and (5) to consider infectious disease consultation in early pre-transplant evaluation process.
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